Results 131 to 140 of about 467,321 (167)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation. [PDF]

Int J Mol Sci, 2021
Wittenborn EC, Marletta MA.
europepmc   +1 more source

Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021. [PDF]

Front Pharmacol, 2022
Jia XY, Liu YM, Wang YF, An JY, Peng KL, Wang H.   +5 more
europepmc   +1 more source

Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis. [PDF]

Rheumatology (Oxford)
Kaufman J, Nabozny G, Tran-Manh C, Liebel C, Zhou X, Daley LA, Wang CT, Ebenezer DL, Delic D, Wohnhaas CT, Trinh-Minh T, Distler JHW.   +11 more
europepmc   +1 more source

The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage. [PDF]

J Hypertens
Hüttl M, Miklovič M, Gawryś O, Molnár M, Škaroupková P, Vaňourková Z, Kikerlová S, Malínská H, Kala P, Honetschlägerová Z, Sadowski J, Hošková L, Sandner P, Melenovský V, Táborský M, Šnorek M, Červenka L.   +16 more
europepmc   +1 more source

Soluble Guanylate Cyclase Stimulator, BAY41-8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload. [PDF]

Pharmacol Res Perspect
Martišková A, Sýkora M, Andelová N, Ferko M, Gawrys O, Andelová K, Kala P, Červenka L, Szeiffová Bačová B.   +8 more
europepmc   +1 more source

The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial. [PDF]

Nephrol Dial Transplant
Gansevoort RT, Wheeler DC, Debén FM, Speeckaert M, Thomas D, Berger M, Klein S, Friedrichs F, Paraschin K, Schmieder RE.   +9 more
europepmc   +1 more source

Controlling the trans effect induced by nitric oxide and carbon monoxide: H93C myoglobin versus H-NOX sensors and soluble guanylate cyclase. [PDF]

Protein Sci
Yoo BK, Lambry JC, Negrerie M.
europepmc   +1 more source

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. [PDF]

Eur Respir J
Humbert M, Hassoun PM, Chin KM, Bortman G, Patel MJ, La Rosa C, Fu W, Loureiro MJ, Hoeper MM.   +8 more
europepmc   +1 more source

The influence of paraventricular nucleus of the hypothalamus soluble guanylate cyclase on autonomic and neuroendocrine responses to acute restraint stress in rats. [PDF]

Eur J Neurosci
Busnardo C, Crestani CC, Fassini A, Scarambone BM, Packard BA, Resstel LBM, Herman JP, Correa FMA.   +7 more
europepmc   +1 more source

Expression of soluble guanylate cyclase (sGC) and its ability to form a functional heterodimer are crucial for reviving the NO-sGC signaling in PAH. [PDF]

Free Radic Biol Med
Sumi MP, Tupta B, Song K, Mavrakis L, Comhair S, Erzurum SC, Liu X, Stuehr DJ, Ghosh A.   +8 more
europepmc   +1 more source